In the early human embryonic/fetal pancreas, we studied 1) the ontogenetic pattern of the endocrine cells and the evolution of the endocrine mass, and 2) the morphogenetic pattern of development and, more precisely, the complex relationship of the epithelial mass with the surrounding mesenchyme. We studied 15 pancreases between 7 and 11 weeks of development (WD) by double immunohistochemistry. Epithelial cells in these pancreatic anlage were detected by cytokeratin staining, and differentiated endocrine cells were detected by insulin, glucagon, somatostatin, and pancreatic polypeptide staining. Proliferation was quantified using a nuclear marker, the Ki-67 antibody. At this early stage, the pancreas is made up of an epithelial mass composed of central ducts intermingled with a loose mesenchyme and peripheral ducts surrounded by a dense peripancreatic mesenchyme. Hormone-containing cells appear in the epithelium at 8 WD. Newly differentiated endocrine cells coexpress insulin, glucagon, and somatostatin; endocrine differentiation starts within the central ducts of the epithelial mass, at a distance from the dense peripancreatic surrounding mesenchyme. The fraction of the primitive endocrine cells undergoing proliferation is low (5% of the insulin cells at 8 WD, 3% at 11 WD), which is in favor of massive diff e r e n t i a t i o n as the major mechanism for increasing endocrine mass. By contrast, the nonendocrine epithelial cells have a higher rate of proliferation; the epithelial cells in contact with the dense peripancreatic surrounding mesenchyme show more proliferation activity than those within the central part of the epithelial mass (at 11 WD, labeling index: periphery 65% vs. center 15%, P < 0.001). In conclusion, the patterns of endocrine diff e rentiation and epithelial proliferation observed within the human pancreas early in development suggest that the mesenchyme plays a role in these phenomena. D i a b e t e s 4 9 :2 2 5-232, 2000
A s is the case for other endodermal organs, the development of the pancreas is thought to result from interactions between the epithelium and its associated mesenchyme. In murine models, this has long been suspected (1). It has been shown in vivo, in rodent models, that the mesenchyme is required for proper differentiation of the primitive epithelium into exocrine pancreas (2). It has also been shown, in an in vitro rat model, that both the inductive effect of the mesenchyme on the proper development of the exocrine tissue and its repressive effect on the development of the endocrine cells are mediated by soluble factors (3). However, the events underlying the early period of pancreas development have not yet been fully elucidated in humans.
The pancreas develops from the fusion of distinct endoderm-derived dorsal and ventral diverticula (4). In humans, by day 35 of development, the ventral pancreatic bud begins to migrate backwards and comes into contact and eventually fuses with the dorsal pancreatic bud during the sixth week of development (5,6). The dorsal bud gives rise to the major part of the head, the body, and the tail of the future pancreas, whereas the ventral bud gives rise to the inferior part of the head of the future pancreas. Over the last 30 years there have been a number of studies describing the ontogenetic pattern of endocrine cells in the human pancreas (7-13). Indeed, a description of the early appearance and development of cells containing the four different hormones has been performed from 8 to 40 weeks of gestation (9,10). More recently, differentiated human islet cells were shown to have a very limited capacity for proliferation from 12 to 41 weeks of gestation (14) . This very low mitotic activity of the islet cells has been advanced as an argument that the main increase of the islet cell mass during fetal life in the developing pancreas is brought about by islet cell neogenesis from hormone negative precursor cells (14) . However, in the existing data, the early period from 7 to 11 weeks of gestation is not well described, partly because of the scarcity of the material and partly because of the imprecise determination of gestational age. This imprecision is in sharp contrast with the recent identification of several transcription factors thought to control early pancreatic development (15). The role of one of these, PDX1, seemed to be confirmed when a patient with a pancreatic aplasia was shown to harbor a deleterious mutation in the PDX1 gene (16).
Early pancreatic development is a crucial period during which the primitive pancreas progresses from hormone negativity to synthesis of all the hormones later to be secreted by the pancreas. We therefore undertook a study of the early human fetal pancreas between weeks 7 and 11 of development 1) to describe the ontogenetic pattern of the four endocrine cell types and the evolution of the endocrine mass during this period, and 2) to describe the morphogenetic development pattern during the same period and, more prec i s e l y, the complex relationship between the epithelial mass and the surrounding mesenchyme.
Microwave treatment allows retrieval of protein antigenicity in paraffin-embedded tissue (21). The streptavidin-biotin-peroxidase complex was used with diaminobenzidine as chromogen, producing brown nuclear staining (Biogenex). For the second step of the double staining procedure, a monoclonal antibody to either insulin or glucagon, or a polyclonal antibody to either somatostatin, cytokeratin, synaptophysin, or pancreatic polypeptide was applied (Ta b l e 1). Alkaline phosphatase with fast red was used for antibody detection. In one experiment, as a first step, an antibody to vimentin (a mesenchymal cells marker) was applied, and for the second step, the antibody to cytokeratin (an epithelial cells marker) was used. The immunohistochemical staining was controlled by parallel staining using only the secondary reagents (no primary antibodies) and by parallel staining using only the chromogen (no primary antibodies or secondary reagents). All the controls were negative. For Ki-67, a positive control was made by staining human tumors or human intestine, both of which have numerous proliferating cells. For the endocrine markers, positive controls were made on sections of normal human newborn or adult pancreases. I m m u n o fluorescence staining. To detect the coexpression of more than one hormone in any cell type, pancreas sections were incubated 2 h with either monoclonal anti-insulin and polyclonal anti-somatostatin, monoclonal antiglucagon and polyclonal anti-insulin, or monoclonal anti-glucagon and polyclonal anti-somatostatin antibodies (Ta b l e 1). After being washed in PBS solution with Tween 0.1%, the slides were incubated for 30 min with the second antibodies We counted in a similar way the percentage of glucagon cells expressing insulin, insulin cells expressing somatostatin, somatostatin cells expressing insulin, glucagon cells expressing somatostatin, and somatostatin cells expressing glucagon. The double fluorescent staining was carried out on three consecutive sections of two pancreases of the same age, from the middle region of the pancreas. The percentage was determined by counting 50-300 cells per pancreas. Surface quantific a t i o n . The insulin cell and epithelial cell surfaces (duct cells expressing cytokeratin) were measured using a DMRB microscope (Leica Microsystems, Rueil-Malmaison, France) equipped with a color video camera connected to a Quantimet 500 MC computer (screen magnification 10), as previously described (22). All of the sections on which double immunostaining for insulin and Ki-67 had been performed were quantified. The insulin and epithelial cell areas were expressed in square micrometers or millimeters. The frontal sections from the dorsal part of the pancreas (periphery of the organ) through the central part of the pancreas (center of the organ) to the ventral part (periphery of the organ) were quantifie d .
The insulin cell surface area was also normalized with regard to the epithelial surface. The total number of insulin-containing cells was counted and normalized per unit of epithelial surface to take into account the spatial heterogeneity of endocrine cell location within the pancreas (see R E S U LT S) .
R E S U LT S
Ontogenetic pattern of the endocrine cells Chronological appearance of the endocrine cells. A t 7 and 8 WD, the pancreas consisted of ducts lined by pyramidal cells (Fig. 1A and B) . From 8 WD, the ducts were embedded in a loose mesenchyme (Fig. 1B and C) 
B A C D E F
pancreatic ducts were branched and started to form a lobular pattern (Fig. 1C) . The lobular organization of branching ducts became apparent by 10 WD and was clearly defined at 11 WD (Fig. 1D) . After exhaustive analyses of all sections of the whole pancreas, no immunoreactive hormone was detected at 7 WD (Fig. 1A) . Between 8 and 11 WD, endocrine cells appeared either as single cells or as cell clusters but did not form islets of Langerhans. The first endocrine cells were seen at 8 WD when immunoreactive insulin, glucagon, and somatostatin were detected in three out of four of the pancreases tested (Fig. 1B) . Pancreatic polypeptide was detected from 9 WD and onward. At that stage, the hormonecontaining cells were found either in the epithelial structure (ducts) or in cell groups in contact with or distant from the ducts (Fig. 1D) . Hormonal coexpression. At 8 WD, 92% of cells marked with the anti-insulin antibody were also marked with the antiglucagon antibody (Fig. 1E) , and correspondingly, 97% of cells marked with the anti-glucagon antibody were also marked with the anti-insulin antibody. All cells marked with the antiinsulin antibody were also marked with the anti-somatostatin a n t i b o d y, and correspondingly, 93% of cells marked with the anti-somatostatin antibody were also marked with the antiinsulin antibody. All cells marked with the anti-glucagon antibody were also marked with the anti-somatostatin antibody, and correspondingly, 92% of cells marked with the antisomatostatin antibody were also marked with the antiglucagon antibody. At 9 WD and thereafter, percentages of cells coexpressing more than one hormone dropped dramatically: 11% of cells marked by the anti-insulin antibody were also marked by the anti-glucagon antibody, and 10% of cells marked with the anti-glucagon antibody were also marked with the anti-insulin antibody (Fig. 1F) ; 6% of cells marked with the anti-insulin antibody were also marked with the antisomatostatin antibody at 11 WD. Endocrine cell proliferation. Endocrine cell density and endocrine surface increased dramatically between 8 and 11 WD, from 20 insulin cells/mm 2 of epithelial surface to more than 600. Double immunocytochemical staining revealed that the cell proliferation marker Ki-67 was detectable in nuclei from insulin-, glucagon-, somatostatin-, and synaptophysin-positive cells ( Fig. 2A for somatostatin-positive cells, not shown for the other hormonal cell types). Synaptophysin-positive nerve cells were recognized morphologically and were not included in the counts. The percentage of hormone-expressing cells seen to be proliferating remained low from their appearance at 8 WD to 11 WD. Indeed, 5% of the insulin cells were Ki-67-positive at 8 WD (out of 40 insulin-containing cells present in three out of four pancreases), and 3% at 11 WD (out of 7,000 insulin-containing cells counted) (Fig. 2B) .
Morphogenetic pattern of development in the early human pancreas
Spatial heterogeneity of the endocrine cells in the pancreas throughout early development. From 7 to 11 WD, the pancreas consists of an epithelial tube surrounded by mesenchyme. At 8 WD and onward, the pancreas is made up of an epithelial mass, composed of central ducts intermingled with a loose mesenchyme and peripheral ducts surrounded by a dense peripancreatic mesenchyme ( Fig. 3A and B). The endocrine cells can be seen to be dispersed in heterogeneous groups. Indeed, hormone-containing cells were seen in the central epithelial structures (central ducts) and were surrounded by a rim of epithelial structures (peripheral ducts) in which no endocrine differentiation had occurred ( F i g . 3A a n d C) . As shown in Fig. 4 , the dispersion of each cell type was q u a n t i fied in two ways. The absolute number of endocrine cells, as measured by the surface of insulin-positive cells, was higher in the center of the pancreatic organ than at the periphery of the pancreatic organ ( Fig. 4A and C 
; see sectioning of the pancreas and surface quantification in R E S E A R C H D E S I G N A N D M E T H O D S)
. Also when expressed as insulin-positive cell surface per unit of epithelial surface, the insulin-containing cell density increased from the periphery to the center of the pancreatic organ. This allowed us to exclude the possibility that a sampling bias might explain the observed pattern (F i g . 4B and D) .
The endocrine cells were located in the more central ductal epithelial structures sometime in contact with the loose interductular mesenchyme but at a distance from the dense peripancreatic surrounding mesenchyme. Identical patterns were obtained for the other 10 insulin-containing pancreases analyzed and quantified in the same way (Fig. 4 , data shown for two pancreases).
With increasing developmental age (from 8 to 11 WD), the endocrine surface increased in the center of the pancreatic organ and toward the more peripheral areas of the pancreatic organ (Fig. 5) . These findings are consistent with a centrifugal evolution of the endocrine mass in the early developing p a n c r e a s . Spatial heterogeneity in the capacity for proliferation of the epithelial duct cells in the human pancreas during early development. The proliferating cells in the pancreatic ducts also appeared to be heterogeneously distributed. We therefore quantified the proliferating cells in the ducts in close relation with the dense peripancreatic surrounding mesenchyme (peripheral ducts) and those in the ducts located in the center of the tissue (central ducts). Proliferation of the peripheral ducts was much greater than that of central ducts (65 vs. 15% Ki-67-labeled duct cells at 11 WD, P < 0.001). The same phenomenon was observed between 7 and 11 WD (Fig. 6 ) . In this study we examined early human pancreatic development in a window of time in which the pancreas evolves from a hormone-negative to a hormone-expressing stage.
The above results concerning the apparition of each endocrine cell type are concordant with certain studies (9,10) but discordant with others, in which no glucagon-containing cells were detected at 8 WD or in which cells containing somatostatin and pancreatic polypeptide were detected at 7 WD (11,13). The antibodies used, the sensitivity of the immunohistochemistry method, and also the dating of the developmental age may account for these differences. Concerning the dating method used here, up to 9 WD, the morphological data and in vivo ultrasonographical measurements were concordant and thus gave a very precise developmental age (5, 6, 17, 18) . This rigorous technique for dating the fetus thus allows us to be confident that insulin-containing cells are already present at 8 WD. At this stage, almost all the insulin cells coexpress glucagon and somatostatin. The majority of insulin-containing cells stained negative for the other pancreatic hormones after 9 WD, which is regarded as a sign of maturation by many authors (22,24,25). We used immunohistochemical staining of Ki-67 to detect proliferating human fetal cells in vivo and for comparison with previous data obtained from older human pancreases at 12-41 WD (14). Ki-67 immunoreactivity is thought to give an approximate estimate of the fraction of cells that are cycling (20) . The data obtained here showing low proliferation activity of the endocrine cells (5 and 3% of the insulincontaining cells at 8 and 11 WD, respectively) are consistent with previously published data (14). Such weak proliferation activity even during very early pancreatic development is in line with previous in vitro studies on fetal and adult human islet cells, in which endocrine cell proliferation was found to be very low (24, (26) (27) (28) . These data, taken together with the very large increase in the density and number of endocrine cells found here (even if the precise cell cycle timing of early fetal endocrine cells is not known, precluding exact calculation), are consistent with the hypothesis that increased endocrine cell mass in the early developing human pancreas results from massive differentiation of unspecialized cells.
The spatial organization of endocrine differentiation within the developing pancreas is a major finding of this s t u d y. In all of the studied pancreases in which endocrine differentiation had occurred, the endocrine cells were located in the central epithelial ducts of the pancreas separated from the surrounding dense peripancreatic mesenchyme by epithelial structures (ducts) that were free of endocrine differentiation. This was revealed by the systematic analysis of very early developing pancreases, which show relatively simple tissue organization, i.e., an epithelial tube with little branching and duct cells embedded in a loose mesenchyme, surrounded by a dense peripancreatic mesenchyme. It has been shown in a rat in vitro model that recapitulates embryonic pancreatic development that the mesenchyme has a repressive effect on the development of the endocrine tissue (3). The current study suggests that this could indeed be the case in the early development of the human pancreas.
M o r e o v e r, we show here a very high proliferation ability of the duct cells, particularly of those located in close vicinity to the dense peripancreatic mesenchyme where the proliferation is two to three times more than in the central ducts and constant from 7 to 11 WD. This suggests that the mesenchyme has an inductive effect on the proliferation of the duct cells, and therefore it probably plays a role in the proper growth and subsequent differentiation of the exocrine pancreas, which ultimately represents the greatest mass of the pancreas. This is consistent with the mesenchyme effect observed on the exocrine pancreas in a rat in vitro model (3).
Proliferation and differentiation of progenitor cells in the developing murine embryonic anterior pituitary have also been shown to respect a spatial organization (29). In the case of the pituitary, this pattern was shown to be linked to spatial and temporal restriction in fibroblast growth factor (FGF) and bone morphogenetic protein-mediated signals from adjacent neural and mesenchymal signaling centers (29). It is of interest to note that in the developing rat pancreas, FGF2 promotes pancreatic epithelial cell proliferation (30). In the rat model, follistatin can mimic both inductive and repressive effects of the mesenchyme. Follistatin might thus represent one of the mesenchyme factors required for exocrine tissue development while exerting a repressive effect on endocrine cell differentiation (3). Whether this spatial duct and endocrine development pattern is linked only to soluble mesenchyme-secreted factors or to differences in the intrinsic differentiation ability of the epithelium related to location remains to be established.
In conclusion, we have shown that in the human pancreas 1) hormone-containing cells appear at 8 WD when they coexpress insulin, glucagon, and somatostatin; 2) the ability of the primitive endocrine cells to proliferate is very limited, thereby suggesting that the major mechanism behind the increase in endocrine mass is differentiation from hormonenegative precursor cells; 3) there is a spatial and temporal pattern of endocrine differentiation that starts within the central epithelial ducts at a distance from the dense peripancreatic surrounding mesenchyme and shows a centrifugal evolution from 8 to 11 WD; and 4) there is very intense duct proliferation in proximity to the surrounding mesenchyme: this suggests that both the inductive effect of the mesenchyme on the development of the primitive epithelial tissue (ducts) and its repressive effect on the development of the endocrine cells are operating in the developing early human pancreas, as in the previously described rodent model (3). This study was supported by a Juvenile Diabetes Foundation grant (198207) to R.S. and by the Aide aux Jeunes Diabétiques, with a grant to M.P. and an educational grant to L.B.-B. We wish to thank Professor M. Peuchmaur and his team from the pathology department at the Hôpital Robert Debré for continuous help during this work. We are indebted to the medical staff in the department of gynecological surgery at the Hôpital Robert Debré, directed by Professor Blot, and to Dr. B e n i fla in the department of gynecological surgery at the Hôpi-tal Bichat for providing human embryonic and fetal tissues.
